Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,799.50
  • Today's Change-1.00 / -0.06%
  • Shares traded94.27k
  • 1 Year change16.25%
  • Beta0.8941
Data delayed at least 20 minutes, as of Jul 19 2019 13:18 BST.
More ▼

Key statistics

As of last trade Hikma Pharmaceuticals PLC (HIK:LSE) traded at 1,799.50, -13.86% below its 52-week high of 2,089.00, set on Nov 08, 2018.
52-week range
Today
1,474.00Jul 19 20182,089.00Nov 08 2018
Markit short selling activity
Low
Med
High
Open1,811.50
High1,816.50
Low1,786.50
Bid1,798.50
Offer1,800.50
Previous close1,800.50
Average volume550.09k
Shares outstanding242.27m
Free float133.21m
P/E (TTM)19.21
Market cap4.32bn GBP
EPS (TTM)0.9288
GBP
Annual div (ADY)29.51
GBX
Annual div yield (ADY)1.64%
Div ex-dateApr 04 2019
Div pay-dateMay 22 2019
Data delayed at least 20 minutes, as of Jul 19 2019 13:18 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Hold at 1,577.00 on 14 Mar 2019Read the full article

Board of Directors

1/11

Said Darwazah, Executive Chairman

2/11

Siggi Olafsson, Chief Executive Officer

3/11

Mazen Darwazah, Executive Vice Chairman, President of MENA

4/11

Ali Al-Husry, Non-Executive Director

5/11

Dr. Jochen Gann, Non-Executive Director

6/11

Robert Pickering, Nomination and Governance Committee Chair, Senior Independent Director

7/11

Dr. Pamela Kirby, Remuneration Committee Chair, Independent Non-Executive Director

8/11

Pat Butler, Audit Committee Chair, Independent Non-Executive Director

9/11

John Castellani, CREC Chair, Independent Non-Executive Director

10/11

Nina Henderson, Independent Non-Executive Director

11/11

Peter Speirs, Company Secretary

Contact

Address:
Hikma Pharmaceuticals PLC
1 New Burlington Place
London
W1S 2HR

T: +44 (0) 20 7399 2760
F: +44 (0) 20 7399 2761
E: investors@hikma.uk.com
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.